<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367239">
  <stage>Registered</stage>
  <submitdate>10/10/2014</submitdate>
  <approvaldate>28/10/2014</approvaldate>
  <actrnumber>ACTRN12614001139662</actrnumber>
  <trial_identification>
    <studytitle>Effect of in vitro embryo culture conditions on metabolism of optimal human embryos in infertile couples</studytitle>
    <scientifictitle>Which cultivation conditions could yield more optimal human embryos of infertile couples using different levels of oxygen ( 5% versus 20% O2) by using morphokinetics and a method of profiling amino acids</scientifictitle>
    <utrn>U1111-1162-7559 
</utrn>
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>infertility</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fertility including in vitro fertilisation</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Randomized cultivation of human embryos with different levels of oxygen (5% versus 20%) from the day of fertilization (day 0) till the day of embryo transfer (day 5). On the day 3, the best embryos (based on morphokinetics) will be cultivated separately till the day 5. On the day 5, blastocyst media of the transffered embryo will be analyzed by LC-MS/MS ( liquid chromatography-mass spectrometry) to identify specific metabolic amino acid profile of the transffered embryos.</interventions>
    <comparator>Comparator treatment is cultivation of embryos with 20% O2 as it was standard treatment for many years.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical Pregnancy Rate (CPR) - assessed by serum hCG assay and fetal ultrasound</outcome>
      <timepoint>4 weeks after embryo transfer</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Fertilization Rate (FR) - assessed by checking pronuclear stage of oocytes on day 1 by microscope evaluation</outcome>
      <timepoint>24 hours after oocite pick-up</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Amino acid profiles of transffered embryos - assessed by LC-MS/MS (liquid chromatography-mass spectrometry)</outcome>
      <timepoint>On the day 5 of cultivation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Implantation Rate (IR) - assessed by fetal ultrasound</outcome>
      <timepoint>4 weeks after embryo transfer</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Live birth rate (LBR) - assessed by live birth of a child</outcome>
      <timepoint>About 9 months after embryo transfer</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Infertile patients in stimulated cycles</inclusivecriteria>
    <inclusiveminage>22</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>42</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Severe male infertility (azoospermia, cryptozoospermia)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by computer
</concealment>
    <sequence>Simple randomisation using a randomisation table created by computer software </sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Number of participants is defined by power analysis of chi quadrat test and with respect to number of patients in our clinic.Number of participants is 100. Female participants are divided in 3 age categories: 22-34, 35-39 and 40-42. Number of patients of each group should be over 30.
Data will be analyzed by Kolmogorov-Smirnov Test and due to the given results parametric or non-parametric test will be used: chi quadrat test, t-test, Mann-Whitney U test, Kruskal-Wallis test.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>3/11/2014</anticipatedstartdate>
    <actualstartdate>1/03/2015</actualstartdate>
    <anticipatedenddate>22/12/2016</anticipatedenddate>
    <actualenddate>18/10/2016</actualenddate>
    <samplesize>100</samplesize>
    <actualsamplesize>92</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>18/07/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Zagreb</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>NINA GELO</primarysponsorname>
    <primarysponsoraddress>Clinical Hospital Centre Zagreb, Petrova 13, 10 000 Zagreb
</primarysponsoraddress>
    <primarysponsorcountry>Croatia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Clinical Hospital Centre Zagreb</fundingname>
      <fundingaddress>Petrova 13, 10 000 Zagreb</fundingaddress>
      <fundingcountry>Croatia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Cultivation of embryos in the new incubator using 5% O2, unlike the previous 20% O2, opens the
question whether this increases biological potential of embryos for implantation or not and which
methods for determination of this potential are more accurate and reliable. Given that the existing data
on the benefits of cultivation with 5% O2 are contradictory considering the age of the patient, it is
necessary to carry out research on a larger number of samples of all ages. Current methodology for
determining the biological potential of embryos -morphology assessment should be supplemented by
an objective method that is not subject to the subjective judgment of biologists embryologist. Such a
potential method is determination of the metabolic profile of amino acids of embryos by analyzing the
spent media in which they are cultivated. It is necessary to determine the sensitivity and applicability of
such methods. Given the fact that we work with human material it is necessary that a method is
absolutely non-invasive.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Zagreb, School of Medicine</ethicname>
      <ethicaddress>Salata 3, 10 000 Zagreb</ethicaddress>
      <ethicapprovaldate>17/06/2014</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>13/05/2014</ethicsubmitdate>
      <ethiccountry>Croatia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>University Hospital Centre Zagreb</ethicname>
      <ethicaddress>Kispaticeva 12, 10 000 Zagreb</ethicaddress>
      <ethicapprovaldate>17/06/2014</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>15/05/2014</ethicsubmitdate>
      <ethiccountry>Croatia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Ms</title>
      <name>NINA GELO</name>
      <address>Clinical Hospital Centre Zagreb
Petrova 13, 10 000 Zagreb</address>
      <phone>+385 1 460 4765 or +385 91 252 1235</phone>
      <fax>+385 1 2376 267</fax>
      <email>ngelo@kbc-zagreb.hr</email>
      <country>Croatia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>NINA GELO</name>
      <address>Clinical Hospital Centre Zagreb

Petrova 13, 10 000 Zagreb</address>
      <phone>+385 1 460 4765</phone>
      <fax>+385 1 2376 267</fax>
      <email>ngelo@kbc-zagreb.hr</email>
      <country>Croatia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>NINA GELO</name>
      <address>Clinical Hospital Centre Zagreb
Petrova 13, 10 000 Zagreb</address>
      <phone>+385 1 460 4765</phone>
      <fax>+385 1 2376 267</fax>
      <email>ngelo@kbc-zagreb.hr</email>
      <country>Croatia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>NINA GELO</name>
      <address>Petrova 13, 10 000 Zagreb</address>
      <phone>+385 1 460 4765</phone>
      <fax>+385 1 2376 267</fax>
      <email>ngelo@kbc-zagreb.hr</email>
      <country>Croatia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>